Gene Solutions Welcomes Dominic Price to Board of Directors

Gene Solutions is thrilled to announce the addition of Dominic Price to its Board of Directors, following the unanimous approval of the existing board members. Dominic brings over three decades of distinguished experience in the banking and consulting industries, enhancing our strategic vision and leadership team.

Dominic’s illustrious career spans over 25 years at JPMorgan, where he held senior executive positions across London, Singapore, Mumbai, and Ho Chi Minh City. His extensive career has endowed him with a broad spectrum of management skills and deep expertise in running trading businesses, investment banking teams, and overseeing JPMorgan’s operations in India and Vietnam. Additionally, he brings valuable board experience from his roles at IDFC Private Equity in India and Masan Corporation in Vietnam. A notable highlight of Dominic’s career at JPMorgan includes spearheading the public listing of Tata Consultancy Services, the world’s largest IT services company, and facilitating major M&A transactions such as Tata Sons’ acquisition of Land Rover Jaguar. Dominic’s expertise encompasses fund raising, public listings, risk management, investor relations, corporate governance, and leadership development—all of which will be invaluable as Gene Solutions aims to solidify its position as a leading genetic testing provider in Southeast Asia.

In 2017, after leaving full-time employment at JPMorgan, Dominic founded Halracott Private Limited, a consulting practice initially based in Singapore and later moved to the UK. Through Halracott, Dominic has advised founders across various sectors, including Arctic Green Energy, Ethixbase 360, Claritas Healthtech, and Altin Biosciences. His consultancy work reflects his commitment to supporting innovative and sustainable business practices.
Dominic, a UK citizen born in Saigon, has a profound connection to Asia, having spent much of his life working in the region. His extensive experience, coupled with his deep-rooted understanding of the Asian market, will greatly benefit Gene Solutions as we strive to achieve our growth and development goals.

Dr. Nghia Nguyen, CEO & Co-founder of Gene Solutions adds: “We are happy and confident that Dominic’s diverse background, global exposure and proven track record in banking and consulting will provide Gene Solutions with the strategic insights and leadership necessary to navigate the full potential of the clinical genomics industry.”

We warmly welcome Dominic to our Board of Directors and look forward to his contributions in driving our mission forward.

Mr. Dominic Price, Mr. Chris Freund (Mekong Capital founder), Dr. Nghia Nguyen, Dr. Hoa Giang, Mr. Hoa Nguyen (Gene Solutions Board of Directors) and Ms. Ashley Pham (Mekong Capital Investment Director) at MKC Investors Day 11 June 2024.
Mr. Dominic Price, Mr. Chris Freund (Mekong Capital founder), Dr. Nghia Nguyen, Dr. Hoa Giang, Mr. Hoa Nguyen (Gene Solutions Board of Directors) and Ms. Ashley Pham (Mekong Capital Investment Director) at MKC Investors Day 11 June 2024.

About Gene Solutions:

Gene Solutions is a leading genetic testing company in South-East Asia that empowers healthcare decisions with accessible and critical insights. The company enables access to next-generation genetic tests that support reproductive health and clinical oncology. They offer unique tests for reproductive health, including highly accuracy Non-invasive Prenatal Testing (NIPT), carrier screening, single-gene disorders detection and assited reproduction testing (PGT for IVF). In the field of clinical oncology, they provide personalized minimal residual disease (MRD) detection, comprehensive genomic profiling (CGP) and multi-cancer early detection (MCED) tests using advanced ctDNA technology. With six international standard Next-Generation Sequencing (NGS) Labs in Southeast Asia, Gene Solutions is committed to enhancing healthcare with their innovative genetic solutions.

Media Contact:

LATEST News

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

New Study Validates Gene Solutions’ Upgraded ctDNA Workflow Behind K-TRACK and K-4CARE

Peer-reviewed findings published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), demonstrate broader ctDNA analysis, improved recurrence prediction, and greater flexibility with or without tumor tissue. SINGAPORE, 14 October 2026 – Gene Solutions announced the publication of a new peer-reviewed study validating the upgraded ctDNA workflow behind K-TRACK, K-4CARE, and K-TRACK Blood Only. Published in The Journal of Liquid Biopsy, an official journal of the International Society of Liquid Biopsy (ISLB), the study evaluated how Gene Solutions’ new hybrid-capture sequencing workflow and VarSURE bioinformatics pipeline improve upon its previous amplicon-based ctDNA method.

Read More

Biomarker and ctDNA Testing: A Personalized Approach to Cancer Care

Cancer diagnosis often brings many questions: Which treatment is most suitable for me? Is my treatment working? Has cancer changed? Could it come back? Every person’s cancer is different. Even when two people have the same type of cancer, their tumors may have different biological features. These differences can influence how the cancer behaves and how it responds to treatment. Biomarker and circulating tumor DNA, or ctDNA, testing may help doctors better understand these differences. Together, these tests may support more personalized treatment decisions and provide additional information as the cancer changes over time. Why can the same cancer respond

Read More
Gene Solutions NIPT preterm birth prenatal health

Gene Solutions Study Finds Preterm-Birth Signals in Routine triSure NIPT Data

A Gene Solutions study published in American Journal of Obstetrics & Gynecology (AJOG) Global Reports finds cell-free DNA fragmentomic patterns associated with spontaneous preterm birth, pointing to a potential path toward earlier pregnancy-risk assessment. SINGAPORE, Sept. 25, 2026 /PRNewswire/ — Gene Solutions, a global biotechnology company providing precision cell-free DNA solutions through multi-omics and artificial intelligence to improve pregnancy care, cancer detection and precision medicine, today announced the publication of a study showing the potential to assess the risk of spontaneous preterm birth from cell-free DNA fragmentomic signals already present in routine first-trimester non-invasive prenatal testing (NIPT) data. Published in AJOG Global Reports, the

Read More